Skip to content

Nonclinical Testing Terminology

Proposed rule · Federal Register document 2026-19349

Published
09/22/2026
Comments due
12/07/2026
39 days left
Pages
16

Summary

Proposed rule.

The Food and Drug Administration (FDA, Agency, or we) is proposing to substitute references to "animal" tests or studies with "nonclinical" tests or studies, add a definition of the terms "nonclinical test" and "nonclinical study," and make other comparable or conforming amendments in certain safety and reporting sections of its regulations. The proposed rule would also substitute "nonclinical" for "preclinical" and "in vitro" for consistency in terminology. These proposed amendments align with recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) and are intended to remove an emphasis, in certain places, on the use of animal testing as the only scientific methodology to assess the safety of a drug in the nonclinical setting. These changes may also foster the development and use of scientifically valid new testing methodologies, potentially improving predictive accuracy of product safety testing while replacing, reducing, or refining animal use. The proposed rule would add no new requirements.

Read the official textPDF on GovInfoHow to comment

Details

Type
Proposed rule
Docket
Docket No. FDA-2026-N-5347
Regulation ID (RIN)
0910-AJ27
CFR parts
21 CFR 312, 21 CFR 314, 21 CFR 315, 21 CFR 361, 21 CFR 601
Topics
Administrative practice and procedure, Biologics, Confidential business information, Drugs, Exports, Imports, Investigations, Labeling, Medical research, Prescription drugs, Radiation protection, Reporting and recordkeeping requirements, Safety

This page summarizes a Federal Register document. Only the official Federal Register text has legal effect. Comment deadlines can be extended or reopened by a later notice.

Source: Office of the Federal Register, via the Federal Register API · Last updated 09/22/2026